Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it bought back 80,000 H-shares on 7 May 2026 through on-market transactions on the Hong Kong Stock Exchange. The purchase price ranged between HK$3.46 and HK$3.47 per share, representing a volume-weighted average of approximately HK$3.465, for a total consideration of about HK$0.28 million.

Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) declined by 0.0018 % to 4.468 billion shares, while treasury shares rose to 54.40 million. The company’s overall issued share count remains unchanged at 4.522 billion shares, as the repurchased stock is being held in treasury rather than cancelled.

The repurchase forms part of a mandate approved on 27 May 2025 that authorises the company to buy back up to 451.56 million shares. To date, Weigao Group has repurchased 47.75 million shares under this mandate, equivalent to 10.57 % of the share capital outstanding on the mandate date.

In line with Hong Kong Listing Rule 10.06(3)(a), Weigao Group is restricted from issuing new shares or disposing of treasury shares until 7 June 2026.